NeoGenomics, Inc. reported Q2 2026 adjusted EBITDA of $57 million, up 200% YoY, with revenue reaching $206 million, an 80% increase driven by strong demand across segments.
NeoGenomics, Inc. reported Q2 2026 adjusted EBITDA of $57 million, representing a remarkable 200% increase from the same quarter last year and surpassing consensus estimates. This substantial growth highlights the company's ongoing operational strength across all segments, positioning it for an optimistic outlook as demand for rare earth materials continues to rise.
Key Takeaways
- Adjusted EBITDA reached $57 million, a 200% increase year-over-year, marking an all-time high for the company.
- Revenue was $206 million, an increase of nearly 80% compared to Q2 2025, driven by strong performance across all business segments.
- Rare Metals Segment achieved record quarterly performance with revenue of $106 million, up almost 200% year-over-year, aided by tight global supply and elevated pricing.
- Guidance Reaffirmed: The company expects full-year adjusted EBITDA to be in the range of $140 million to $150 million, up from a prior range of $100 million to $110 million.
- Increased Capacity Investments: The company is investing in expanding its European Permanent Magnet Facility and bonded magnet business, with a focus on meeting growing market demands.
Revenue Growth Driven by Strong Demand
NeoGenomics delivered impressive revenue of $206 million for Q2 2026, representing a nearly 80% year-over-year increase. This growth was fueled by robust demand across all segments, particularly in the Rare Metals segment, which saw revenues increase nearly 200% to $106 million. The continued high pricing environment and increased volume contributions were key factors in achieving this milestone, as highlighted by Jonathan Baksh, CFO: > "This exceptional performance reflects healthy underlying demand and sustained strength in pricing across all of our business segments."
| Metric | Q2 2026 | YoY | QoQ |
|---|---|---|---|
| Revenue | $206 million | +80% | N/A |
| Adjusted EBITDA | $57 million | +200% | N/A |
| Adjusted EPS | $0.55 | +162% | N/A |
Rare Metals Segment Achieves Record Performance
The Rare Metals segment was a standout performer during the quarter, delivering record revenues of $106 million, marking a nearly 200% increase year-over-year. Adjusted EBITDA for this segment reached $44 million, up over 300% from the prior year. The growth was supported by a 40% year-over-year increase in hafnium volumes alongside sustained high pricing, which reflects increasing emphasis on supply chain resilience across end markets such as aerospace and industrial applications. Management noted that > "This strength reflects increasing emphasis on supply chain resilience and secure access to critical materials."
Strategic Investments to Support Future Growth
Management's commitment to strategic investments is evident as the company announced ongoing expansions in its European Permanent Magnet Facility and bonded magnet business. The financing of $115 million Canadian raised in May is earmarked for equipment upgrades to support these expansions. The company is set to increase production capacity significantly, from 2,000 tons to 5,000 tons, to meet the accelerating demand across the rare earth permanent magnet sectors. As noted by Rahim Suleiman, CEO, the facility positions NeoGenomics to capture long-term growth in permanent magnet demand across various industries.
Guidance Affirmation Signals Confidence
The company has increased its full-year adjusted EBITDA guidance to a range of $140 million to $150 million, up from a prior range of $100 million to $110 million. This upward revision demonstrates confidence in sustained operational performance and market demand. Management emphasized the importance of contracted volumes secured through 2026 and into 2027, providing visibility for future earnings. The company anticipates potential for exceeding the top end of this guidance, which indicates a strong outlook for the remainder of the year.
Frequently Asked Questions
Did NeoGenomics, Inc. beat earnings estimates in Q2 2026?
Yes, NeoGenomics reported adjusted earnings per share of $0.55, significantly above the consensus estimate of $0.21, marking a 162% increase year-over-year.
What drove the record performance in the Rare Metals segment?
The Rare Metals segment achieved record performance due to a nearly 200% increase in revenue, driven by strong volumes and sustained high pricing in a tight global supply environment.
What is the current outlook for NeoGenomics' European Permanent Magnet Facility?
The facility is on track to increase production capacity significantly and is expected to launch multiple customer programs into commercial production by the end of 2026, positioning the company for long-term growth.
How has NeoGenomics adjusted its guidance for 2026?
The company raised its full-year adjusted EBITDA guidance to $140 million to $150 million, reflecting strong operational performance and market demand throughout the first half of the year.
How is NeoGenomics addressing market demand for bonded magnets?
NeoGenomics is investing in its bonded magnet business, which has seen strong growth and is expected to play a crucial role in various applications, including robotics and drones, amid rising demand for rare earth materials.
The company’s strategic positioning and focus on growth opportunities suggest a promising trajectory, making it a company to watch in the evolving rare earth market landscape.
This analysis is based on public earnings call materials and is not investment advice.
